Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Phase-locking of magnetic islands diagnosed by ECE-imaging.

Tobias B, Grierson BA, Muscatello CM, Ren X, Domier CW, Luhmann NC Jr, Zemedkun SE, Munsat TL, Classen IG.

Rev Sci Instrum. 2014 Nov;85(11):11D847. doi: 10.1063/1.4892438.

PMID:
25430260
2.

Developing normalized strength scores for neuromuscular research.

Andres PL, English R, Mendoza M, Florence J, Malkus E, Schierbecker J, Siener C, Malspeis S, Schoenfeld DA, Munsat TL, Cudkowicz ME.

Muscle Nerve. 2013 Feb;47(2):177-82. doi: 10.1002/mus.23516. Epub 2012 Nov 21.

PMID:
23168880
3.

Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials.

Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, Cudkowicz ME.

Muscle Nerve. 2012 Jan;45(1):81-5. doi: 10.1002/mus.22253.

PMID:
22190312
4.

Lead exposure as a risk factor for amyotrophic lateral sclerosis.

Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, Sandler DP.

Neurodegener Dis. 2005;2(3-4):195-201.

PMID:
16909025
5.

Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes.

Kamel F, Umbach DM, Lehman TA, Park LP, Munsat TL, Shefner JM, Sandler DP, Hu H, Taylor JA.

Environ Health Perspect. 2003 Aug;111(10):1335-9.

6.

Lead exposure and amyotrophic lateral sclerosis.

Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP.

Epidemiology. 2002 May;13(3):311-9.

PMID:
11964933
7.

Slowing down ALS--is this good or bad?

Munsat TL.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Mar;2 Suppl 1:S19-22. Review.

PMID:
11465919
8.

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review. No abstract available.

PMID:
11464847
9.

Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome.

Trojan DA, Collet J, Pollak MN, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman NR.

J Neurol Sci. 2001 Jan 1;182(2):107-15.

PMID:
11137515
10.

Dietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosis.

Longnecker MP, Kamel F, Umbach DM, Munsat TL, Shefner JM, Lansdell LW, Sandler DP.

Neuroepidemiology. 2000 Jul-Aug;19(4):210-6.

PMID:
10859501
11.

The global burden of disease study: implications for neurology.

Menken M, Munsat TL, Toole JF.

Arch Neurol. 2000 Mar;57(3):418-20.

PMID:
10714674
12.

The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group.

Miller RG, Anderson FA Jr, Bradley WG, Brooks BR, Mitsumoto H, Munsat TL, Ringel SP.

Neurology. 2000 Jan 11;54(1):53-7.

PMID:
10636125
13.

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.

Miller RG, Munsat TL, Swash M, Brooks BR.

J Neurol Sci. 1999 Oct 31;169(1-2):2-12. Review.

PMID:
10540001
14.

A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.

Trojan DA, Collet JP, Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Granger C, Robinson A, Finch L, Ducruet T, Cashman NR.

Neurology. 1999 Oct 12;53(6):1225-33.

PMID:
10522877
15.

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence-based review).

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Muscle Nerve. 1999 Aug;22(8):1104-18. No abstract available.

PMID:
10417794
16.

The relationship of lower-limb muscle force to walking ability in patients with amyotrophic lateral sclerosis.

Jette DU, Slavin MD, Andres PL, Munsat TL.

Phys Ther. 1999 Jul;79(7):672-81.

PMID:
10416576
17.

Association of cigarette smoking with amyotrophic lateral sclerosis.

Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP.

Neuroepidemiology. 1999;18(4):194-202.

PMID:
10364720
18.

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.

Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, Borasio GD, Bradley WG, Bromberg MB, Brooks BR, Kasarskis EJ, Munsat TL, Oppenheimer EA.

Neurology. 1999 Apr 22;52(7):1311-23. No abstract available.

PMID:
10227612
19.

Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy.

Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP, Pegoraro E, Hunter RG, Munsat TL, Brown RH Jr.

Neurology. 1998 Aug;51(2):589-92.

PMID:
9710042
20.

Lower extremity muscle force measures and functional ambulation in patients with amyotrophic lateral sclerosis.

Slavin MD, Jette DU, Andres PL, Munsat TL.

Arch Phys Med Rehabil. 1998 Aug;79(8):950-4.

PMID:
9710168
21.

Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis.

Aoki M, Lin CL, Rothstein JD, Geller BA, Hosler BA, Munsat TL, Horvitz HR, Brown RH Jr.

Ann Neurol. 1998 May;43(5):645-53.

PMID:
9585360
22.

Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study.

Cudkowicz ME, Warren L, Francis JW, Lloyd KJ, Friedlander RM, Borges LF, Kassem N, Munsat TL, Brown RH Jr.

Neurology. 1997 Jul;49(1):213-22.

PMID:
9222193
23.

Effect of increased maxillo-mandibular relationship on isometric strength in TMD patients with loss of vertical dimension of occlusion.

Abduljabbar T, Mehta NR, Forgione AG, Clark RE, Kronman JH, Munsat TL, George P.

Cranio. 1997 Jan;15(1):57-67.

PMID:
9586489
24.

Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.

Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, Goodpasture JC.

Neurology. 1996 Nov;47(5):1329-31.

PMID:
8909453
25.

Issues in clinical trial design I: Use of natural history controls. A protagonist view.

Munsat TL.

Neurology. 1996 Oct;47(4 Suppl 2):S96-7. No abstract available.

PMID:
8858059
26.

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.

Miller RG, Bouchard JP, Duquette P, Eisen A, Gelinas D, Harati Y, Munsat TL, Powe L, Rothstein J, Salzman P, Sufit RL.

Neurology. 1996 Oct;47(4 Suppl 2):S86-90; discussion S90-2.

PMID:
8858057
27.

Development of measurement techniques.

Munsat TL.

Neurology. 1996 Oct;47(4 Suppl 2):S83-5. Review. No abstract available.

PMID:
8858056
28.

A comparison of three measures of disease progression in ALS.

Andres PL, Skerry LM, Thornell B, Portney LG, Finison LJ, Munsat TL.

J Neurol Sci. 1996 Aug;139 Suppl:64-70.

PMID:
8899661
29.

Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy.

Wang CH, Xu J, Carter TA, Ross BM, Dominski MK, Bellcross CA, Penchaszadeh GK, Munsat TL, Gilliam TC.

Hum Mol Genet. 1996 Mar;5(3):359-65.

PMID:
8852661
30.

Dystonic postures generated from complex repetitive discharges.

Preston DC, Finkleman RS, Munsat TL.

Neurology. 1996 Jan;46(1):257-8.

PMID:
8559390
31.

Issues in amyotrophic lateral sclerosis clinical trial design.

Munsat TL.

Adv Neurol. 1995;68:209-18. Review. No abstract available.

PMID:
8787231
32.

Overview of the pathogenesis and therapy of amyotrophic lateral sclerosis.

Serratrice GT, Munsat TL.

Adv Neurol. 1995;68:1-5. No abstract available.

PMID:
8787219
33.

Pathogenesis and therapy of amyotrophic lateral sclerosis. Introduction.

Serratrice GT, Munsat TL.

Adv Neurol. 1995;68:xix-xx. No abstract available.

PMID:
8787218
34.

Linkage disequilibrium and haplotype analysis among Polish families with spinal muscular atrophy.

Brzustowicz LM, Wang CH, Matseoane D, Kleyn PW, Vitale E, Das K, Penchaszadeh GK, Munsat TL, Hausmanowa-Petrusewicz I, Gilliam TC.

Am J Hum Genet. 1995 Jan;56(1):210-5.

35.

High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies.

Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL.

Ann Neurol. 1994 Dec;36(6):920-4.

PMID:
7998781
36.

The AAN launches a new education program: CONTINUUM lifelong learning in neurology.

Munsat TL, Mancall EL, DesLauriers MP.

Neurology. 1994 Apr;44(4):771-2. No abstract available.

PMID:
8164845
37.

Assessment of nonallelic genetic heterogeneity of chronic (type II and III) spinal muscular atrophy.

Brzustowicz LM, Mérette C, Kleyn PW, Lehner T, Castilla LH, Penchaszadeh GK, Das K, Munsat TL, Ott J, Gilliam TC.

Hum Hered. 1993 Nov-Dec;43(6):380-7.

PMID:
7904586
38.

Recombinant growth hormone treatment of amyotrophic lateral sclerosis.

Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW.

Muscle Nerve. 1993 Jun;16(6):624-33.

PMID:
8502260
39.

The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials.

Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL.

Neurology. 1993 Apr;43(4):751-5.

PMID:
8469335
40.

Refinement of the spinal muscular atrophy locus to the interval between D5S435 and MAP1B.

Soares VM, Brzustowicz LM, Kleyn PW, Knowles JA, Palmer DA, Asokan S, Penchaszadeh GK, Munsat TL, Gilliam TC.

Genomics. 1993 Feb;15(2):365-71.

PMID:
8449502
41.

Needle muscle biopsy with the automatic Biopty instrument.

Coté AM, Jiménez L, Adelman LS, Munsat TL.

Neurology. 1992 Nov;42(11):2212-3.

PMID:
1436541
42.

Fine-mapping of the spinal muscular atrophy locus to a region flanked by MAP1B and D5S6.

Brzustowicz LM, Kleyn PW, Boyce FM, Lien LL, Monaco AP, Penchaszadeh GK, Das K, Wang CH, Munsat TL, Ott J, et al.

Genomics. 1992 Aug;13(4):991-8.

PMID:
1505990
43.

Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system.

Munsat TL, Taft J, Jackson IM, Andres PL, Hollander D, Skerry L, Ordman M, Kasdon D, Finison L.

Neurology. 1992 May;42(5):1049-53.

PMID:
1579228
44.

Measurement of isometric force in children with and without Duchenne's muscular dystrophy.

Brussock CM, Haley SM, Munsat TL, Bernhardt DB.

Phys Ther. 1992 Feb;72(2):105-14.

PMID:
1549631
45.

International SMA consortium meeting. (26-28 June 1992, Bonn, Germany).

Munsat TL, Davies KE.

Neuromuscul Disord. 1992;2(5-6):423-8. No abstract available.

PMID:
1300191
46.

Spinal muscular atrophy is not the result of mutations at the beta-hexosaminidase or GM2-activator locus.

Kleyn PW, Brzustowicz LM, Wilhelmsen KC, Freimer NB, Miller JM, Munsat TL, Gilliam TC.

Neurology. 1991 Sep;41(9):1418-22.

PMID:
1679910
47.

Poliomyelitis--new problems with an old disease.

Munsat TL.

N Engl J Med. 1991 Apr 25;324(17):1206-7. No abstract available.

PMID:
2011165
48.

Clinical trials in ALS: measurement and natural history.

Munsat TL, Hollander D, Andres P, Finison L.

Adv Neurol. 1991;56:515-9. Review. No abstract available.

PMID:
1853780
49.

Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q).

Munsat TL, Skerry L, Korf B, Pober B, Schapira Y, Gascon GG, al-Rajeh SM, Dubowitz V, Davies K, Brzustowicz LM, et al.

Neurology. 1990 Dec;40(12):1831-6.

PMID:
2247230
50.

Excitotoxins and amyotrophic lateral sclerosis.

Munsat TL, Hollander D.

Therapie. 1990 May-Jun;45(3):277-9. Review.

PMID:
2194313

Supplemental Content

Loading ...
Support Center